title: Outcomes at 2 years of age after repeat doses of antenatal corticosteroids.
abstract: BACKGROUND
  We previously reported the results of a randomized, controlled trial showing that repeat doses of antenatal corticosteroids reduced the risk of respiratory distress syndrome and serious neonatal morbidity. However, data have not been available regarding longer-term effects of this treatment.
  
  
  METHODS
  Women who had received an initial course of corticosteroid treatment 7 or more days previously were randomly assigned to receive an intramuscular injection of corticosteroid (11.4 mg of betamethasone) or saline placebo; the dose was repeated weekly if the mother was still considered to be at risk for preterm delivery and the duration of gestation was less than 32 weeks. We assessed survival free of major neurosensory disability and body size of the children at 2 years of corrected age.
  
  
  RESULTS
  Of the 1085 children who were alive at 2 years of age, 1047 (96.5%) were seen for assessment (521 exposed to repeat-corticosteroid treatment and 526 exposed to placebo). The rate of survival free of major disability was similar in the repeat-corticosteroid and placebo groups (84.4% and 81.0%, respectively; adjusted relative risk, 1.04, 95% confidence interval, 0.98 to 1.10; adjusted P=0.20). There were no significant differences between the groups in body size, blood pressure, use of health services, respiratory morbidity, or child behavior scores, although children exposed to repeat doses of corticosteroids were more likely than those exposed to placebo to warrant assessment for attention problems (P=0.04).
  
  
  CONCLUSIONS
  Administration of repeat doses of antenatal corticosteroids reduces neonatal morbidity without changing either survival free of major neurosensory disability or body size at 2 years of age. (Current Controlled Trials number, ISRCTN48656428 [controlled-trials.com].).
authors: Disciplines of Obstetrics and Gynaecology, University of Adelaide, Women's and Children's Hospital, Adelaide, Australia. caroline.crowther@adelaide.edu.au
authors: Caroline A
authors: CA
authors: Crowther
authors: Lex W
authors: LW
authors: Doyle
authors: Ross R
authors: RR
authors: Haslam
authors: Janet E
authors: JE
authors: Hiller
authors: Jane E
authors: JE
authors: Harding
authors: Jeffrey S
authors: JS
authors: Robinson
mesh_terms: D000328:Adult; D001623:Betamethasone / Q000008:administration & dosage*; D049628:Body Size / Q000187:drug effects*; D002547:Cerebral Palsy / Q000453:epidemiology; D002653:Child Behavior Disorders / Q000453:epidemiology*; D002675:Child, Preschool; D002658:Developmental Disabilities / Q000453:epidemiology* / Q000517:prevention & control; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage*; D006304:Health Status; D006801:Humans; D008297:Male; D011247:Pregnancy; D011295:Prenatal Care
chemical_list: D005938:Glucocorticoids; D001623:Betamethasone